According to a new report North America Liver Disease Diagnostics Market, published by KBV research, the North America Liver Disease Diagnostics Market would witness market growth of 5.8% CAGR during the forecast period (2020-2026).
The US market dominated the North America Endoscopy Market by Country in 2019, and would continue to be a dominant market till 2026. The Canada market is exhibiting a CAGR of 8.5% during (2020 - 2026). Additionally, The Mexico market would witness a CAGR of 7.5% during (2020 - 2026).
The Hospitals market dominated the Canada Liver Disease Diagnostics Market by End User in 2019, growing at a CAGR of 7.8 % during the forecast period. The Laboratories market is expected to witness a CAGR of 8.5% during (2020 - 2026).
The Imaging market dominated the Mexico Liver Disease Diagnostics Market by Diagnosis Technique in 2019, growing at a CAGR of 6.7 % during the forecast period. The Biopsy market is anticipated to witness a CAGR of 7.2% during (2020 - 2026). Additionally, The Endoscopy market would exhibit highest CAGR of 7.5% during (2020 - 2026).
Report Structural Insights: https://www.kbvresearch.com/north-america-liver-disease-diagnostics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, F. Hoffmann-La Roche Ltd., Boston Scientific Corporation, Siemens AG (Siemens Healthineers), Bayer AG, Merck & Co., Inc., Sanofi S.A., Novartis AG, Pfizer, Inc., and Randox laboratories limited.
By End-User
By Diagnosis Technique
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
